Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M40,832Revenue $M15,259Net Margin (%)11.9Z-Score3.3
Enterprise Value $M46,495EPS $3.7Operating Margin %15.7F-Score5
P/E(ttm))21.1Cash Flow Per Share $5.6Pre-tax Margin (%)15.2Higher ROA y-yN
Price/Book4.710-y EBITDA Growth Rate %12.1Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.55-y EBITDA Growth Rate %6.5Current Ratio1.6Lower Leverage y-yY
Price/Cash Flow11.7y-y EBITDA Growth Rate %0.9ROA % (ttm)7.6Higher Current Ratio y-yN
Dividend Yield %2.7Insider Buy (3m)0ROE % (ttm)22.5Less Shares Outstanding y-yY
Payout Ratio %56.0Shares Outstanding M543ROI % (ttm)15.1Gross Margin Increase y-yN

Gurus Latest Trades with BAX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BAXJean-Marie Eveillard 2014-06-30 Add0.18%$71.98 - $75.45
($73.67)
$ 74.61%Add 90872.4%1,000,696
BAXJohn Keeley 2014-06-30 Buy 0.05%$71.98 - $75.45
($73.67)
$ 74.61%New holding, 37150 sh.37,150
BAXScott Black 2014-06-30 Reduce-0.43%$71.98 - $75.45
($73.67)
$ 74.61%Reduce -30.98%123,976
BAXVanguard Health Care Fund 2014-06-30 Sold Out -0.11%$71.98 - $75.45
($73.67)
$ 74.61%Sold Out0
BAXRay Dalio 2014-06-30 Reduce-0.03%$71.98 - $75.45
($73.67)
$ 74.61%Reduce -90.74%5,763
BAXJohn Hussman 2014-06-30 Reduce-0.02%$71.98 - $75.45
($73.67)
$ 74.61%Reduce -50%3,725
BAXDavid Dreman 2014-06-30 Sold Out -0.01%$71.98 - $75.45
($73.67)
$ 74.61%Sold Out0
BAXCharles Brandes 2014-03-31 Buy 0.19%$66.49 - $72.85
($68.75)
$ 74.68%New holding, 204560 sh.204,560
BAXScott Black 2014-03-31 Add0.17%$66.49 - $72.85
($68.75)
$ 74.68%Add 13.41%179,629
BAXDavid Dreman 2014-03-31 Buy 0.01%$66.49 - $72.85
($68.77)
$ 74.68%New holding, 2453 sh.2,453
BAXJean-Marie Eveillard 2014-03-31 Reduce$66.49 - $72.85
($68.77)
$ 74.68%Reduce -85.53%1,100
BAXJohn Hussman 2014-03-31 Reduce-0.49%$66.49 - $72.85
($68.75)
$ 74.68%Reduce -93.07%7,450
BAXVanguard Health Care Fund 2014-03-31 Reduce-0.41%$66.49 - $72.85
($68.75)
$ 74.68%Reduce -77.96%531,100
BAXRay Dalio 2014-03-31 Reduce-0.07%$66.49 - $72.85
($68.77)
$ 74.68%Reduce -67%62,263
BAXScott Black 2013-12-31 Add1.06%$63.89 - $69.47
($66.75)
$ 74.612%Add 776.11%158,392
BAXJohn Hussman 2013-12-31 Reduce-0.54%$63.89 - $69.47
($66.75)
$ 74.612%Reduce -58.26%107,450
BAXJean-Marie Eveillard 2013-12-31 Reduce-0.26%$63.89 - $69.47
($66.75)
$ 74.612%Reduce -99.44%7,600
BAXJames Barrow 2013-12-31 Sold Out -0.22%$63.89 - $69.47
($66.75)
$ 74.612%Sold Out0
BAXVanguard Health Care Fund 2013-12-31 Reduce-0.17%$63.89 - $69.47
($66.75)
$ 74.612%Reduce -24.2%2,410,000
BAXRay Dalio 2013-12-31 Reduce-0.03%$63.89 - $69.47
($66.75)
$ 74.612%Reduce -24.85%188,663
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BAX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BAX Jean-Marie Eveillard 2014-06-301,000,6960.180.18+90872.4%
BAX John Keeley 2014-06-3037,1500.010.05New Buy
BAX Mario Gabelli 2014-06-30243,4000.040.09+7.94%
BAX Charles Brandes 2014-06-30209,9070.040.18+2.61%
BAX Tweedy Browne 2014-06-302,592,1550.484-0.37%
BAX Dodge & Cox 2014-06-303,38200-0.65%
BAX Scott Black 2014-06-30123,9760.021.3-30.98%
BAX John Hussman 2014-06-303,72500.02-50%
BAX Ray Dalio 2014-06-305,76300-90.74%
BAX David Dreman 2014-06-30000Sold Out
BAX Vanguard Health Care Fund 2014-06-30000Sold Out
BAX Meridian Funds 2013-06-308,60000.02
Premium Most recent portfolio changes are included for Premium Members only!


BAX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FORSYTH JOHN DDirector 2014-08-15Sell4,830$74.9-0.32view
Shapazian Carole JDirector 2014-07-25Sell1,645$76.98-3.01view
STALLKAMP THOMAS TDirector 2014-07-24Sell8,300$76.82-2.81view
HANTSON LUDWIGCorporate Vice President 2014-07-09Sell24,693$76-1.76view
STROUCKEN ALBERT P LDirector 2014-05-27Sell3,840$74.410.34view
Shapazian Carole JDirector 2014-05-02Sell5,680$75.28-0.82view
STORM KEES JDirector 2014-04-23Sell5,760$72.453.05view
Devitt Blake EDirector 2014-04-21Sell4,334$73.122.11view
Bufalino Sebastian JCorporate Vice President 2014-03-27Sell21,600$75.1-0.59view
Shapazian Carole JDirector 2013-09-12Sell1,941$71.584.3view

Press Releases about BAX :

    Quarterly/Annual Reports about BAX:

    News about BAX:

    Articles On GuruFocus.com
    Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
    Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
    Abbott: A Brighter Future Aug 28 2014 
    Diamond Hill Capital Comments on Baxter International Inc Jul 25 2014 
    Why I Bought Baxter International Jun 19 2014 
    Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
    Two Stocks On My Watch List For June 2014 May 29 2014 
    Companies That Are Raising Dividends May 16 2014 
    Auxier Asset Management's Auxier Report - First Quarter 2014 May 06 2014 
    4 Top Stocks in the Medical Device Sector Apr 11 2014 

    More From Our Partners
    Baxter and Halozyme Therapeutics Get FDA Approval - Analyst Blog Sep 15 2014 - ZACKS

    More From Other Websites
    Baxter and Halozyme Therapeutics Get FDA Approval Sep 15 2014
    FDA Approves Baxter’s RIXUBIS [Coagulation Factor IX (Recombinant)] for Treatment of Children with... Sep 15 2014
    2:25 am Baxter: FDA approves Baxter's HYQVIA for treatment of adults with primary immunodeficiency Sep 15 2014
    FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency Sep 12 2014
    Momenta Gains on Purchase of Autoimmune Antibodies Sep 11 2014
    Baxter Names its New Spun-off Biopharmaceuticals Company Sep 11 2014
    Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company Sep 10 2014
    Why Baxter International Offers Great Reward for Minimal Risk Sep 08 2014
    Baxter Expects to Grow on Acquisitions and Product Lineups Sep 03 2014
    Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014
    Positive Data on Baxter's Trial for BAX 855 Aug 22 2014
    Long-acting version of Baxter's hemophilia drug succeeds in study Aug 21 2014
    Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life... Aug 21 2014
    Health care company expanding in Alabama Aug 20 2014
    Health care company expanding in Alabama Aug 20 2014
    Baxter International Expands Dialyzers Facility in Alabama Aug 20 2014
    Baxter Announces Hemodialysis Dialyzer Expansion in Opelika, Alabama Aug 19 2014
    Baxter to Present at Morgan Stanley Global Healthcare Conference Aug 18 2014
    Sinopharm, Biostar, Lilly Rise on Medical Modernization in China Aug 18 2014
    3 Stocks Driving The Health Services Industry Higher Aug 11 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Sww
    ReplySww - 2 months ago
    Bax medical devices revenue ~9b, bio science ~7b
    using 3X sales of medical devices company and 4X for drugs company, 27b+28b = 55b market cap,as of June 2014, BAX market cap is 39b, so it can sell for

    72 * (1 + 16/39) = 99

    72 is current stock price, with an upside of around 35%

    so my guess is BAX may be able to sell for around 90 after spin-off.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK